Lina Khan’s tenure at FTC marked by bold critique of pharmacy benefit managers. Despite bipartisan demands for reform, political hurdles persist in tackling PBM’s controversial role in drug pricing.

As Lina Khan, the departing chair of the Federal Trade Commission (FTC), steps down this week, her legacy is marked by a scathing critique of pharmacy benefit managers (PBMs) – a group of intermediaries that hold a peculiar, and arguably controversial, role in the U.S. pharmaceutical landscape.

In the latest FTC report, PBMs are again spotlighted, accused of inflating drug prices and exerting undue influence on independent pharmacies.

Despite bipartisan pressure, the path to reform remains littered with political obstacles.

To the uninitiated, PBMs might seem like mere cogs in the complex machinery of pharmaceutical distribution.

Yet, they wield significant influence, managing the prescription drug benefits for approximately 275 million Americans.

With their tentacles reaching into the realms of health insurers, pharmacies, and healthcare providers, PBMs have become formidable gatekeepers in the drug supply chain.

The top three—OptumRx, Express Scripts, and CVS Caremark—command an 80% share of the market, a testament to their dominance.

The FTC’s scrutiny reveals troubling practices.

From 2017 to 2022, PBMs reportedly marked up the prices of specialty generic medicines well beyond their acquisition costs, pocketing over $7.3 billion.

Moreover, these entities favored their own affiliated pharmacies with higher reimbursement rates, sidelining independent competitors.

Such practices have not only raised pharmaceutical costs but have also left patients with higher out-of-pocket expenses.

A poignant example lies in the markup of critical medications, like imatinib for chronic myeloid leukemia and lamivudine for HIV, which have become emblematic of the broader issue.

While PBMs claim their strategies save patients money, a closer look reveals a more complex picture.

The practice of spread pricing—charging health plans more than what is reimbursed to pharmacies—has further inflated costs by $1.4 billion.

The debate over PBMs is not new.

For over six years, these entities have faced relentless pressure from federal agencies, the executive branch, and the media.

Yet, despite the noise, substantial reform remains elusive.

Former President Trump loudly criticized PBMs, yet under his watch, the FTC allowed industry consolidation to persist.

Now, with bipartisan discussions once again on the table, optimism cautiously bubbles to the surface.

The question remains: why has action been so slow?

Perhaps it’s the intricate web of interests and the sheer complexity of the pharmaceutical ecosystem that makes reform so daunting.

The recent omission of crucial PBM reform measures from the year-end continuing resolution hints at the political reluctance to disturb the status quo.

Nevertheless, the momentum for change appears to be gathering pace.

Proposed legislation aims to disentangle the conflicting interests of PBMs, health insurers, and pharmacy ownership, while also introducing transparency measures and delinking PBM revenue from drug list prices in Medicare.

It is a bold step, yet whether it will transform into tangible policy remains an open question.

As the pharmaceutical industry grapples with these challenges, the role of PBMs continues to spark debate.

Are they indispensable negotiators reducing net costs, or middlemen exacerbating price hikes?

The truth may lie somewhere in between, but what is clear is that the current model is unsustainable for the long-term financial health of both the industry and the patients it serves.

The coming years will be critical in determining whether PBMs evolve into more transparent and accountable entities or remain the contentious players they are today.

At Global Business & Economics Journal, we contribute to the  future of business and technology with news,  innovative research, expert insights, and thought-provoking analysis.